Abstract：
Pancreatic cancer (PaC) incidence is increasing, but our current screening and diagnostic strategies are not very effective. However, screening could be helpful in the case of PaC, as recent evidence shows that the disease progresses gradually. Unfortunately, there is no ideal screening method or program for detecting PaC in its early stages. Conventional imaging techniques, such as abdominal ultrasound, CT, MRI, and EUS, have not been successful in detecting early-stage PaC. On the other hand, biomarkers may be a more effective screening tool for PaC and have greater potential for further evaluation compared to imaging. Recent studies on biomarkers and artificial intelligence (AI)-enhanced imaging have shown promising results in the early diagnosis of PaC. In addition to proteins, non-coding RNAs are also being studied as potential biomarkers for PaC. This review consolidates the current literature on PaC screening modalities to provide an organized framework for future studies. While conventional imaging techniques have not been effective in detecting early-stage PaC, biomarkers and AI-enhanced imaging are promising avenues of research. Further studies on the use of biomarkers, particularly non-coding RNAs, in combination with imaging modalities may improve the accuracy of PaC screening and lead to earlier detection of this deadly disease.
摘要：
胰腺癌（PaC）发病率正在增加，但我们目前的筛查和诊断策略并不十分有效.然而,筛查在PaC的情况下可能会有帮助，正如最近的证据表明这种疾病逐渐发展。不幸的是,没有理想的筛查方法或程序来检测PaC的早期阶段。常规成像技术，如腹部超声，CT,MRI,和EUS,没有成功检测早期PaC。另一方面,与成像相比,生物标志物可能是更有效的PaC筛查工具,并且具有更大的进一步评估潜力.最近对生物标志物和人工智能（AI）增强成像的研究在PaC的早期诊断中显示出了有希望的结果。除了蛋白质,非编码RNA也被研究为PaC的潜在生物标志物。这篇综述巩固了目前关于PaC筛查模式的文献，为未来的研究提供了一个有组织的框架。虽然传统的成像技术在检测早期PaC方面并不有效，生物标志物和AI增强成像是有希望的研究途径。进一步研究生物标志物的使用，特别是非编码RNA，结合影像学检查可能会提高PaC筛查的准确性,并导致这种致命疾病的早期发现.
